GSK Signs a License Agreement with Hansoh Pharma for HS-20093 to Treat Solid Tumors
Shots:
- GSK & Hansoh Pharma signed an exclusive license agreement for the development & commercialization of HS-20093 across the globe excluding mainland China for the treatment of solid tumors
- As per the agreement, Hansoh will receive an up front payment of $185M & is eligible to receive up to $1.525B as success-based milestone payments plus tiered royalties. Earlier in Oct 2023, both companies signed a license agreement for HS-20089, a B7-H4 targeted ADC, currently under P-II evaluation in solid tumors incl. ovarian & endometrial cancer
- HS-20093, a B7-H3-targeted ADC, is being evaluated in a P-I & II clinical trial for solid tumors China. The results from the P-I (ARTEMIS-001) clinical trial were presented at the ASCO 2023
Ref: GSK | Image: GSK
Related News:- Antengene Entered into a Commercialization Agreement with Hansoh Pharma for Xpovio (selinexor) in the Mainland of China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
